[Acute type A aortic dissection].

Tetsuro Morota; Shinichi Takamoto

Home/Archive/PubMed

PubMed · 15362534

[Acute type A aortic dissection].

Tetsuro Morota·Shinichi Takamoto

View original source ↗Export metadata ↓

Abstract

BACKGROUND: Current surgical results for acute type A aortic dissection has been getting better, though the mortality rate still remains high, up to 10-15% in Japan. Our strategy consists of #1 make the most use of echography for better understanding of hemodynamics; #2 the extent of replacement depends on the site of initial entry; #3 deep hypothermic circulatory arrest and retrograde cerebral perfusion for brain protection. PATIENTS AND METHODS: Between January 2000 and December 2003, 45 consecutive patients were treated. Twelve of them had extended replacement of the arch, and 3 had simultaneous root replacement by means of a composite graft. RESULTS: In hospital mortality was 11% (5 patients). The cause of death was serious organ malperfusion, which had been developed preoperatively, in all patients but 1 who suffered from thoracic aortic obstruction due to newly developed type B aortic dissection. CONCLUSIONS: The determinant of surgical mortality in patients with acute type A aortic dissection is the presence of serious organ malperfusion. Rapid diagnosis and less invasive treatment for malperfusion is the key to improve the results.

Explore related subjects

Acute Disease Adult Aged Aortic Dissection Aorta, Thoracic Aortic Aneurysm, Thoracic Blood Vessel Prosthesis Implantation Cardiac Surgical Procedures Humans Middle Aged Survival Rate English Abstract Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Tetsuro Morota, Shinichi Takamoto. 2004. [Acute type A aortic dissection].. https://pubmed.ncbi.nlm.nih.gov/15362534/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

The effect of acute pain crisis on exhaled nitric oxide levels in children with sickle cell disease.

Exhaled nitric oxide (FE(NO)) has been shown to be decreased in children with sickle cell disease. We sought to evaluate the effect of sickle cell vaso-occlusive crisis (VOC) on FE(NO) levels. We measured FE(NO) levels in 42 children with sickle cell disease, 29 in their baseline health and 13 during an acute VOC. There was no difference in FE(NO) levels between children at baseline (15.12 +/- 9.32 ppb) and those during an acute VOC (15.68 +/- 7.26 ppb; P = 0.794). FE(NO) is not a useful marker of acute VOC in children with sickle cell disease.

Acute Disease↗

PubMed2007

Chemotherapy for myeloid malignancy in children with Fanconi anemia.

BACKGROUND: Children with Fanconi anemia (FA) have a markedly increased risk of developing myeloid malignancies. Historically, patients with FA and myeloid malignancy have extremely poor outcomes. There are currently no clinical trials or case series addressing the use of chemotherapy for children with FA, except in the context of preparative regimens for stem cell transplantation (SCT). In this report we describe the toxicity of a chemotherapy approach for patients with FA and myeloid malignancy to achieve cytoreduction prior to SCT. PATIENTS AND METHODS: Four patients with FA and myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) were treated with chemotherapy (fludarabine 30 mg/m(2) and cytosine arabinoside 300 mg/m(2) each on days 2-4 and granulocyte-colony stimulating factor (G-CSF) 5 microg/kg on days 1-5), termed reduced intensity FLAG prior to SCT. RESULTS: The chemotherapy was well tolerated with expected hematologic toxicity and no measurable toxicity in other organs. Two of the three patients with AML cleared blasts from their bone marrow. Reduction in marrow cellularity was also achieved in one patient with hypercellular MDS. CONCLUSION: These data indicate that children with FA and myeloid malignancy can tolerate chemotherapy and achieve clearance of disease. It remains unclear whether pre-SCT chemotherapy improves currently poor survival rates for SCT in FA patients with myeloid malignancies and further studies are needed to determine if there is a clinical role for this strategy.

Acute Disease↗

PubMed2007

Misspecified regression model for the subdistribution hazard of a competing risk.

We consider a competing risks setting, when evaluating the prognostic influence of an exposure on a specific cause of failure. Two main regression models are used in such analyses, the Cox cause-specific proportional hazards model and the subdistribution proportional hazards model. They are exemplified in a real data example focusing on relapse-free interval in acute leukaemia patients. We examine the properties of the estimator based on the latter model when the true model is the former. An explicit relationship between subdistribution hazards ratio and cause-specific hazards ratio is derived, assuming a flexible parametric distribution for latent failure times.

Acute Disease↗